Using the SomaScan® Assay to identify protein biomarkers and create risk scores for Chronic Obstructive Pulmonary Disease (COPD) and Emphysema
ABSTRACT
COPD and emphysema are lung diseases related to chronic exposure to tobacco smoke or air pollution. The World Health Organization anticipates that COPD will be the number three cause of death worldwide by 2030; however, the majority of smokers and people exposed to air pollution do not develop COPD or emphysema. To better understand why only some people develop disease, we used SomaScan® v4.0 (4,776 human proteins) to identify plasma biomarkers of disease status as well as severity and progression in 6,017 subjects from the COPDGene cohort. Because we were able to identify hundreds of individual biomarkers, the majority of which explained only a small percentage of the phenotypes, we used penalized regression (LASSO) to develop protein risk scores, which typically include 200-300 of the most influential proteins. These protein risk scores explained as much as 40-50% variance of disease.
In this webinar you will
- Learn the basic clinical features and pathophysiology of COPD and emphysema
- Understand how the SomaScan Assay can be used to discover biomarkers
- Consider caveats on how to design good proteomic discovery studies and what potential biases should be considered
- Learn how to use penalized regression (LASSO) to develop protein risk scores
Russ Bowler, M.D., Ph.D.
Russell Bowler, M.D., Ph.D. obtained a B.S. in mathematical and computational sciences from Stanford University, a M.D. from the University of California at San Francisco (UCSF), and a Ph.D. in Cell and Developmental Biology from the University of Colorado (CU). He completed his internal medicine residency at UCSF and a pulmonary and critical care fellowship from CU.
The mission of Dr. Bowler’s lab is to understand the mechanisms of how cigarette smoke leads to the development of chronic obstructive pulmonary disease (COPD), the third leading cause of death in the United States. His team has generated genetic, genomic, and metabolic profiles on 10,000 subjects in the NIH sponsored COPDGene cohort and used these Omics data to identify novel diagnostic and therapeutic targets.
In 2020, Dr. Bowler and collaborators formed the SomaScan® Proteomics Consortium to promote collaboration among prospective cohort studies that follow participants for a range of outcomes and perform SomaScan profiling of individuals. The consortium facilitates an open exchange of ideas, knowledge, and results in order to accelerate the study of proteomics profiles associated with chronic disease phenotypes.
More webinars
WebinarEvaluation of precision and correlation for the latest proteomic platforms
The field of proteomics is rapidly advancing, enabling precise measurement of thousands of proteins, particularly those in higher abundance. This webcast will explore significant differences in precision within and across the latest large-scale proteomic platforms and their intercorrelations, based on blind duplicate split assays of the leading modified aptamer-based 11K and antibody proximity ligation-based 5K platforms. Each platform exhibits distinct strengths and limitations, requiring careful consideration prior to implementation in individual studies.
WebinarScaling Proteomics: Balancing Performance and Measuring Enough Proteins
As proteomics platforms have advanced, the number of proteins measured and sample throughput have dramatically increased. However, have sacrifices or trade-offs been necessary to make these gains? To find out, Stephen Williams will analyze how the performance of proteomics platforms has changed over time, comparing precision, sensitivity and specificity as throughput increases.
WebinarFrom discovery to clinical insights – the power of integrating proteomics and genomics data
The value of adding high-plex proteomics to existing genomics data and how proteogenomic approaches accelerate drug target discovery and repurposing. Watch this presentation given by Maik Pietzner, PhD, at ESHG 2024.